Sotio Announces Clinical Collaboration With MSD To Evaluate Il-15 Superagonist, SOT101, In Combination With Keytruda In Patients With Solid Tumors; Phase 2 Aurelio-04 Study Will Be Conducted In Us And Selected European Countries And Will Begin In 1H 2022

by | Dec 8, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.